US Cardiac Biomarker Market Report 2021: By Key Players, Application, Type, Market Share, Forecast to 2027

The US cardiac biomarker market is estimated to grow significantly at a CAGR of around 7.2% during the forecast period. The major factors that propel the market growth include the high prevalnece of CVDs and heart related diseases in the country coupled with robust healthcare healthcare expenditure. According to the CDC about half of the people who develop heart failure die within 5 years of diagnosis. Heart failure costs the nation an estimated $30.7 billion each year. This total includes the cost of healthcare services, medications to treat heart failure, and missed days of work. High healthcare expenditure in the US enabling the growth of the market. According to the Centre for Disease Control & Prevention (CDC), the US national healthcare expenditure was around $3.3 trillion in 2016. The US has the highest healthcare spending across the globe. In the US per capita, healthcare expenditure is around $10,348 per person, in 2016. The high healthcare expenditure raises the demand for advanced diagnosis technologies such as cardiac biomarkers that further peoples the market growth in the country.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/us-cardiac-biomarker-market

The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the US cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on Application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/us-cardiac-biomarker-market

The companies which are contributing to the growth of the US cardiac biomarker market include Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories, Inc., Creative Diagnosis, Critical Diagnostics, Danaher Corp., LifeSign LLC, Meso Scale Diagnostics LLC, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.

Market Segmentation
US Cardiac Biomarker Market by Type
• Creatine kinase (CK-MB)
• Troponins(T,I)
• Myoglobin
• Natriuretic peptides (BNP & NT-PROBNP)
• Ischemia modified albumin
• Others

US Cardiac Biomarker Market by Application
• Myocardial infraction
• Congestive heart failure
• Acute coronary syndrome
• Atherosclerosis
• Others

US Cardiac Biomarker Market by Location of Testing
• Laboratory testing
• Point of care testing

Company Profiles
• Abbott Laboratories
• Becton, Dickinson and Co.
• Bio-Rad Laboratories, Inc.
• Creative Diagnosis
• Critical Diagnostics
• Danaher Corp.
• LifeSign LLC
• Meso Scale Diagnostics LLC
• Myriad RBM
• Thermo Fisher Scientific Inc.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/us-cardiac-biomarker-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.